Report: Biopharma Quarter: Key Trends and Events of the Fourth Quarter of 2008 TOC

Executive Summary
- Strategic Considerations
- Stakeholder Implications
Introduction
Events Perspective
- On the Political Front: Focus on Themes of the U.S. Elections
  - Expanded Access
  - Cost Containment
  - Cost-Effective, Quality Care
  - Support for Innovation
- On the Economic Front: Quantifying the Impact of the Recession
- On the Approvals Front: Latisse Became the Latest Entry in the Lifestyle Drugs Category
- On the International Front: Focus on Chinese Pharma Manufacturing
Deals Perspective
- Deals by Company
- Deal Type
  - Acquisitions
  - Collaborations and Licensing
- Deals by Therapeutic Area - Oncology Focus
- Product Deals
Generics Perspective: Pro-Generics Governments Boost the Generics Industry
- Increased Big Pharma Involvement in Generics
- U.S. Biosimilars Guidelines Delayed - For Now
- FDA Clampdowns - A Reaction to the Heparin Fiasco?
- Generic Plavix Reaches European Market Early Through a Legal Loophole
- Japanese Generics Market Starts to Open
Strategy Perspective: Global Economic Crisis Is a Prelude to Greater Challenges for Biopharma
- Biotech Sector: Cash Crunch, Company Crashes, and a Cull
- Pharma Sector: Missing a Master Plan for Necessary Transformation
- Pending Challenges for the Industry

1. Targets of Select Key Cost-Containment Measures in the Major Markets
2. Select PGx-Based Diagnostic Tests
3. Select Companies Working on Stem Cell Technologies and Therapies
4. Select Drugs in Development for Autism
5. Worldwide 2007 Sales of Select “Lifestyle” Drugs
6. Leading Domestic and Multinational Pharmaceutical Companies in China
7. Key Fourth-Quarter Findings of Decision Resources' Emerging Markets Research and Analysis
8. Company Dealmaking Activity, Q4 2008
9. Select Big Pharma Acquisitions, Q4 2008
10. Select Big Pharma Collaborations, Q4 2008
11. Select Big Pharma Licensing, Q4 2008
12. Select Fourth Quarter Oncology Deals, 2008
13. Biosimilar Agents in the European Union and the United States
14. Generic Expansion into Japan, Q4 2008

1. Qualitative Assessment of Implications of U.S. Healthcare Reform for Biopharma
2. Healthcare Statistics in the United States Versus Select Nations That Provide Universal Health Insurance
3. Year in Review: Market Sector Stock Indices
4. Impact of Cost of Care on Access to Care in the United States Versus Select Nations That Provide Universal Health Insurance
5. Fourth-Quarter 2008 U.S. Drug Approval Tallies and Highlights
6. Volume of Pharma and Biotech Deals, 2006-2008
7. Pharma and Biotech Deals Valued Over $100MM, 2006-2008
8. Largest Deals of Q4 2008, by Value
9. Therapeutic Area Focus of Deals, Q4 2008
10. Product Dealmaking Activities Between Companies, Q4 2008
11. Phase of Development of 54 Inlicensed Products, Q4 2008
12. Categories of Inlicensed Products, Q4 2008
13. Most Important Issues and Labeling Requirements for Regulatory Authorities
14. Extensive Layoffs in the Pharmaceutical Industry, 2007-2008

Biopharma Quarter: Key Trends and Events of the Fourth Quarter of 2008